 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 916 | 回復(fù): 4 | ||
| 當(dāng)前只顯示滿足指定條件的回帖，點擊這里查看本話題的所有回帖 | ||
eileenshen新蟲 (初入文壇)
|
[求助]
求助大蝦幫我查找關(guān)于Diamyd公司產(chǎn)品diapep277的1、2、3期臨床報告
|
|
|
求助大蝦幫我查找關(guān)于Diamyd公司產(chǎn)品diapep277的1、2、3期臨床報告 這個藥剛剛完成三期臨床，萬分感激！ 有pharmaprojects數(shù)據(jù)庫的盡量幫幫忙吧 |
回復(fù)此樓» 猜你喜歡
publcif的使用
已經(jīng)有0人回復(fù)
-
求調(diào)劑
已經(jīng)有2人回復(fù)
-
藥理學(xué)論文潤色/翻譯怎么收費?
已經(jīng)有210人回復(fù)
-
會計專碩求調(diào)劑
已經(jīng)有0人回復(fù)
-
《左乙拉西坦注射液制備工藝研究、質(zhì)量控制和穩(wěn)定性研究》下載
已經(jīng)有1人回復(fù)
-
新加坡國立大學(xué)藥學(xué)系化學(xué)生物學(xué)課題組招PhD
已經(jīng)有14人回復(fù)
-
請教酰胺縮合反應(yīng)
已經(jīng)有4人回復(fù)
-
一志愿大連理工制藥工程專碩086002，本科211，總分342
已經(jīng)有0人回復(fù)
-
制藥工程專業(yè)招收調(diào)劑，要求過國家線
已經(jīng)有0人回復(fù)
-
五邑大學(xué)藥物化學(xué)生物學(xué)團隊-李蘭清課題組招收調(diào)劑學(xué)生
已經(jīng)有0人回復(fù)
» 本主題相關(guān)價值貼推薦，對您同樣有幫助:
- 求助28%的氨水PH多少
已經(jīng)有10人回復(fù)
- 求助 環(huán)酸酐與伯胺的開環(huán)閉環(huán)反應(yīng)
已經(jīng)有11人回復(fù)
- 求助：螯合反應(yīng)進行程度的檢測方法？
已經(jīng)有4人回復(fù)
- 求助高手精修晶體
已經(jīng)有3人回復(fù)
- 【求助】用cDNA的ORF序列以基因組DNA為模板 做PCR 為何P不出其對應(yīng)的基因組序列?
已經(jīng)有8人回復(fù)
- 求助：拖尾的峰上面的峰
已經(jīng)有12人回復(fù)
- 求助羥基芍藥苷的結(jié)構(gòu)與抗氧化機理
已經(jīng)有3人回復(fù)
- 求助關(guān)于ACS投稿的版權(quán)協(xié)議
已經(jīng)有14人回復(fù)
- 碩士小妹的第一次SCI，各種求助
已經(jīng)有15人回復(fù)
- 求助，評閱人關(guān)于實驗設(shè)計的的一個問題，為何不用正交實驗
已經(jīng)有4人回復(fù)
- 帶孩子訪學(xué)的蟲友們求助！看看我們怎么辦？
已經(jīng)有17人回復(fù)
- 求助羊毛中的亞氨基（酰胺基）在什么情況下吸附氫離子
已經(jīng)有3人回復(fù)
- 求助sybyl關(guān)于添加形式電荷的問題
已經(jīng)有8人回復(fù)
- 投稿求助 關(guān)于highlights
已經(jīng)有4人回復(fù)
- 【討論和求助】金屬表面微區(qū)電極電位、相間電位的測量方法
已經(jīng)有7人回復(fù)
- 求大蝦指導(dǎo) 一個關(guān)于atoi函數(shù)的問題
已經(jīng)有3人回復(fù)
- 考研成績已出，求助
已經(jīng)有3人回復(fù)
4樓2012-05-06 16:51:07
癡夷子皮
版主 (文壇精英)
老痞
- DRDEPI: 8
- 應(yīng)助: 2016 (講師)
- 貴賓: 5.368
- 金幣: 54487.3
- 散金: 41688
- 紅花: 303
- 沙發(fā): 1206
- 帖子: 32611
- 在線: 4303.7小時
- 蟲號: 674536
- 注冊: 2008-12-14
- 性別: GG
- 專業(yè): 無神論
- 管轄: 人文社科
【答案】應(yīng)助回帖
★
感謝參與，應(yīng)助指數(shù) +1
zhoudeli: 金幣+1, 多謝參與 2012-05-04 10:00:55
感謝參與，應(yīng)助指數(shù) +1
zhoudeli: 金幣+1, 多謝參與 2012-05-04 10:00:55
|
Detailed Information DiaPep227 (AVE-0277) is an hsp60-derived peptide, under development by Andromeda Biotech for the treatment and prevention of Type 1 diabetes (newly-diagnosed or established disease with some remaining endogenous insulin production) and latent adult autoimmune Type 2 diabetes (LADA). It acts by specific modulation of the autoimmune response from a proinflammatory (Th1) type to an anti-inflammatory (Th2) type to maintain residual β-cell function and halt disease progression (The Lancet, 24 Nov 2001, 358, 1749; Press release, Sanofi-Aventis, 19 Apr 2004; Company Web Page, Andromeda, 27 Oct 2008). Clinical Phase III Diabetes, Type 1 Teva A 1st double-blind, placebo-controlled Phase III trial in 456 patients in Europe, Israel and S Africa with newly-diagnosed Type 1 diabetes and LADA, to assess the safety and efficacy of DiaPep227, met its primary endpoint, defined as the change from baseline in C-peptide levels at the end of the study. Significant preservation of C-peptide was demonstrated in patients treated with DiaPep277 compared to the placebo arm. The decline in C-peptide levels was more pronounced in the placebo arm than in the treated group. The difference between the arms reached 0.949nmol/l/20min. This difference reflects a relative preservation of 23.4% compared to placebo. Evaluation of the primary endpoint was performed on patients in the modified ITT population who have at least one measurement post baseline. Additional analyses of clinical, efficacy and safety data from this study are ongoing (Press releases, Andromeda, 23 Jun 2008 & 8 Sep 2009 ; Press release, Andromeda, 22 Nov 2011, http://www.andromedabio.com/page.php?pageID=69). It is in a 2nd randomized, double-blind, placebo-controlled, parallel-group confirmatory Phase III trial (DIA-AID2) in 450 newly diagnosed Type 1 diabetics, in Austria, Belarus, Canada, Czech Republic, Finland, Germany, Hungary, Israel, Italy, Lithuania, Russia, Spain and the US, to assess DiaPep277 1mg sc x24mth on safety. The primary endpoint is beta cell preservation of function (Press release, Andromeda, 31 May 2010, http://www.andromedabio.com/page.php?pageID=56; Company Web Page, Andromeda, 5 May 2011, http://andromedabio.com/clinical_trials.php; ClinicalTrials.gov, 5 May 2011, http://clinicaltrials.gov/ct2/show/NCT01103284). Completion of patient recruitment is anticipated by the 1st half of 2012 (Press release, Andromeda, 22 Nov 2011, http://www.andromedabio.com/page.php?pageID=69). Final data is expected in 2014 or by the end of 2015 (Company presentation, Evotec, 8 Feb 2012, Page 16, http://evotec.sissy.bgcc.at/uplo ... on_February_e.pdf). First Phase III data are expected in 2012 (Press release, Evotec, 12 May 2011, http://www.evotec.com/archive/en ... e-business/2155/1). It is in an extension study in Israel, S Africa (submitted for approval) and Europe (planned) in patients who completed 2yr of treatment in the previous Phase III trial and still maintain beta cell function (Company Web Page, Anrdromeda, 10 Feb 2009). Phase II Data are expected in 2012 (Company Web Page, Evotec, 25 May 2011, http://www.evotec.com/articles/e ... -partnerships/4/6). In combined analysis from Phase II trials, DiaPep277 results in a dose-dependent improvement in C-peptide levels. DiaPep77 1mg q 3mth was the most effective regimen (10th BIO-Europe (Cologne), 2004). Evotec In a terminated Phase II trial in Germany, Italy and the UK, and a US Phase II trial, in LADA patients, there were no safety issues in >250 patients (2nd Qtr Res, Aventis, 2002; 10th BIO-Europe (Cologne), 2004; ClinicalTrials.gov Web Page, 13 Feb 2007, NCT00058981). Diabetes, Type 1 Sanofi Six Phase II studies in newly diagnosed and established adult Type 1 diabetics and 2 clinical trials in children with newly diagnosed Type 1 diabetes were conducted (BIO 2003 (Washington, DC); 2nd Qtr Res, Aventis, 2002; 10th BIO-Europe (Cologne), 2004). Diabetes, Type 1 Evotec In a placebo-controlled, randomized, double-blind, 10mth Phase II trial in 35 recently-diagnosed Type 1 diabetics, DiaPep227 at mth 0, 1 and 6 + daily insulin injections resulted in C-peptide concentration increases from 0.66 to 0.93nM cf a decrease of 1.12 to 0.26nM with placebo. The need for insulin injections increased over 10mth from 0.37 to 0.67U/kg daily in the placebo group cf an increase from 0.34 to 0.43U/kg in the treated group. DiaPep227 arrested disease progression and prevented further destruction of insulin-producing pancreatic β-cells (Press releases, Peptor, 22 Nov 2001 & 14 Jan 2002). Phase I It was well tolerated in Phase I trials (BIO 2003 (Washington, DC)). |
2樓2012-05-04 09:24:38
癡夷子皮
版主 (文壇精英)
老痞
- DRDEPI: 8
- 應(yīng)助: 2016 (講師)
- 貴賓: 5.368
- 金幣: 54487.3
- 散金: 41688
- 紅花: 303
- 沙發(fā): 1206
- 帖子: 32611
- 在線: 4303.7小時
- 蟲號: 674536
- 注冊: 2008-12-14
- 性別: GG
- 專業(yè): 無神論
- 管轄: 人文社科
【答案】應(yīng)助回帖
★ ★ ★ ★ ★ ★ ★ ★
eileenshen: 金幣+8, ★★★很有幫助, 非常感謝你的幫助 2012-05-04 14:50:01
eileenshen: 金幣+8, ★★★很有幫助, 非常感謝你的幫助 2012-05-04 14:50:01
|
http://g.zhubajie.com/urllink.php?id=12300407koak830c54h3e2qa pharmaprojects報告 |
3樓2012-05-04 09:26:55
癡夷子皮
版主 (文壇精英)
老痞
- DRDEPI: 8
- 應(yīng)助: 2016 (講師)
- 貴賓: 5.368
- 金幣: 54487.3
- 散金: 41688
- 紅花: 303
- 沙發(fā): 1206
- 帖子: 32611
- 在線: 4303.7小時
- 蟲號: 674536
- 注冊: 2008-12-14
- 性別: GG
- 專業(yè): 無神論
- 管轄: 人文社科
5樓2012-05-06 17:17:19
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 394求調(diào)劑 +3 | 好事多磨靜候佳?/a> 2026-03-26 | 5/250 |
|
|---|---|---|---|---|
|
[考研] 調(diào)劑求院校招收 +4 | 鶴鯨鴿 2026-03-28 | 4/200 |
|
|
|
[考研] 286求調(diào)劑 +12 | PolarBear11 2026-03-26 | 12/600 |
|
|
|
[考研] 調(diào)劑 +3 | 好好讀書。 2026-03-28 | 3/150 |
|
|
|
[考研] 【求調(diào)劑】085601材料工程專碩 | 總分272 | +6 | 腳滑的守法公民 2026-03-27 | 6/300 |
|
|
|
[考博] 26申博 +3 | 加油沖�。� 2026-03-26 | 3/150 |
|
|
|
[考研] 考研化學(xué)308分求調(diào)劑 +10 | 你好明天你好 2026-03-23 | 12/600 |
|
|
|
[考研] 化學(xué)308分求調(diào)劑 +8 | 你好明天你好 2026-03-23 | 9/450 |
|
|
|
[考研] 305求調(diào)劑 +5 | 哇盧卡庫 2026-03-26 | 5/250 |
|
|
|
[考研] 348求調(diào)劑 +4 | 小懶蟲不懶了 2026-03-27 | 5/250 |
|
|
|
[考研] 314求調(diào)劑 +3 | 溪云珂 2026-03-26 | 3/150 |
|
|
|
[考研] 材料求調(diào)劑 +5 | .m.. 2026-03-25 | 5/250 |
|
|
|
[考研] 324求調(diào)劑 +5 | hanamiko 2026-03-26 | 5/250 |
|
|
|
[碩博家園] 北京林業(yè)大學(xué)碩導(dǎo)招生廣告 +6 | kongweilin 2026-03-26 | 8/400 |
|
|
|
[考研] 329求調(diào)劑 +5 | 1() 2026-03-22 | 5/250 |
|
|
|
[考研] 化學(xué)工程085602 305分求調(diào)劑 +17 | RichLi_ 2026-03-25 | 17/850 |
|
|
|
[考研] 一志愿 南京郵電大學(xué) 288分 材料考研 求調(diào)劑 +3 | jl0720 2026-03-26 | 3/150 |
|
|
|
[考研] 299求調(diào)劑 +4 | 15188958825 2026-03-25 | 4/200 |
|
|
|
[考研] 一志愿中南大學(xué)化學(xué)學(xué)碩0703總分337求調(diào)劑 +7 | niko- 2026-03-22 | 7/350 |
|
|
|
[考研] 300分，材料，求調(diào)劑，英一數(shù)二 +5 | 超贊的 2026-03-24 | 5/250 |
|